Login to Your Account

Financings Roundup

Fate Therapeutics Joins Biopharma's IPO Runway

By Staff Reports

Thursday, August 15, 2013
Hoping to follow in the footsteps of two other companies focused on stem cells – Verastem Inc. and Stemline Therapeutics Inc. – that successfully completed their initial public offerings (IPOs) in 2012 and 2013 respectively, San Diego-based Fate Therapeutics Inc. filed its S-1 with the SEC to raise up to $69 million in an IPO.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription